All IndicationsInfectious DiseasePhase 3Phase 3Phase 3Phase 2
🦠
Covid19
3
Companies
4
Drug Programs
3
Phase 3
0
Upcoming PDUFAs
Competitors
VIR
Vir Biotechnology, Inc.
VIR-7831 (sotrovimab)
HSCSW
HeartSciences Inc.
Convalescent Plasma
SVA
SINOVAC BIOTECH LTD
Two doses of pilot scale inactivated SARS-CoV-2 vaccine at the schedule of day 0,14 in elderly
VIR
Vir Biotechnology, Inc.
Sotrovimab (Gen1)
| Company | Drug | Phase | Designations | Timeline | Trial ID |
|---|---|---|---|---|---|
| VIR Vir Biotechnology, Inc. | VIR-7831 (sotrovimab) | Phase 3 | — | — | — |
| HSCSW HeartSciences Inc. | Convalescent Plasma | Phase 3 | — | — | — |
| SVA SINOVAC BIOTECH LTD | Two doses of pilot scale inactivated SARS-CoV-2 vaccine at the schedule of day 0,14 in elderly | Phase 3 | — | — | — |
| VIR Vir Biotechnology, Inc. | Sotrovimab (Gen1) | Phase 2 | — | — | — |
Development Stage Distribution
Phase 3
3
Phase 2
1
PDUFA Timeline
No upcoming PDUFA dates for this indication.
Not financial advice
Signals are probabilistic and based on historical data — past performance doesn't guarantee future results. Do your own research.